Related Experiment Video
Updated: Jun 7, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Progress in the treatment of bleeding disorders
1Medical Affairs, CSL Behring, King of Prussia, Pennsylvania, USA. Garrett.Bergman@cslbehring.com
Thrombosis Research
|November 2, 2010
Summary
Current research in coagulation therapy focuses on improving quality of life for patients with hemophilia and von Willebrand disease (VWD). New therapies and studies aim to enhance treatment efficacy and patient outcomes.
Area of Science:
- Hematology and Thrombosis
- Pharmacology and Drug Development
Background:
- Plasma-derived and recombinant coagulation factors have revolutionized bleeding disorder management.
- Significant clinical challenges persist, driving current research in coagulation therapy.
- Quality of life remains a key concern for adolescents and young adults with hemophilia A.
Purpose of the Study:
- To evaluate the impact of life transitions on the quality of life in young patients with hemophilia A.
- To assess the safety and efficacy of novel von Willebrand factor/factor VIII concentrate (Biostate®).
- To investigate the benefits of a novel fusion protein (rIX-FP) for hemophilia B treatment.
Main Methods:
- Prospective, non-interventional studies (HyQoL-Europe, HyQoL-Canada) examining quality of life.
- A clinical development program (SWIFT) comprising four trials for hemophilia A and VWD.
- Development and evaluation of a recombinant factor IX-albumin fusion protein (rIX-FP).
Main Results:
- Ongoing research aims to understand how life events affect quality of life in hemophilia A patients.
- New therapies like Biostate® and rIX-FP are under investigation for safety and efficacy.
- rIX-FP demonstrates a favorable pharmacokinetic profile with a longer half-life.
Conclusions:
- Improved interventions and counseling are needed to mitigate negative impacts of life transitions on patients.
- Novel coagulation factor concentrates offer potential for enhanced treatment and patient compliance.
- Research endeavors focus on developing improved therapies for bleeding disorders, aiming for better clinical outcomes.
Related Concept Videos
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...